Indivior Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Joe Ciaffoni
Chief executive officer
US$18.9m
Total compensation
| CEO salary percentage | 3.60% |
| CEO tenure | 1yr |
| CEO ownership | 0.05% |
| Management average tenure | 1yr |
| Board average tenure | 2.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$252m |
| Dec 31 2025 | US$19m | US$680k | US$210m |
| Sep 30 2025 | n/a | n/a | US$128m |
| Jun 30 2025 | n/a | n/a | US$108m |
| Mar 31 2025 | n/a | n/a | -US$7m |
| Dec 31 2024 | US$4k | n/a | US$7m |
Compensation vs Market: Joe's total compensation ($USD18.87M) is above average for companies of similar size in the German market ($USD2.19M).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
CEO
Joe Ciaffoni (54 yo)
Mr. Joseph J. Ciaffoni, also known as Joe, served as Independent Non-Executive Director at Indivior Pharmaceuticals, Inc. (formerly known as Indivior PLC) since December 17, 2024 until May 2025 and serves...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1yr | US$18.87m | 0.046% € 1.8m | |
| Chief Financial Officer | 5.9yrs | US$3.59m | 0.23% € 9.1m | |
| Chief Scientific Officer | 11.4yrs | US$4.18m | 0.17% € 6.9m | |
| Chief Legal Officer | 4.4yrs | US$3.52m | 0.037% € 1.4m | |
| Chief Commercial Officer | less than a year | US$5.32m | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief Integrity & Compliance Officer | less than a year | no data | no data | |
| Chief Human Resources Officer | 1.7yrs | no data | no data | |
| Executive Vice President of Corporate Affairs | less than a year | no data | no data | |
| Company Secretary | 1yr | no data | no data |
Experienced Management: E7P's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1yr | US$18.87m | 0.046% € 1.8m | |
| Independent Non-Executive Director | 1.3yrs | US$186.70k | 0.017% € 666.2k | |
| Lead Independent Director | 5.2yrs | US$251.56k | 0.0079% € 310.5k | |
| Independent Non-Executive Director | less than a year | US$140.00k | 0.0015% € 60.2k | |
| Independent Non-Executive Director | 3.9yrs | US$220.47k | 0.0047% € 184.6k | |
| Independent Non-Executive Director | 5.2yrs | US$217.51k | 0.014% € 543.8k | |
| Independent Non-Executive Chairman | 1.9yrs | US$441.03k | 0.012% € 464.7k | |
| Independent Non-Executive Director | 2.5yrs | US$196.79k | 0.0031% € 120.0k |
Experienced Board: E7P's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 07:10 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indivior Pharmaceuticals, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Graham Glyn Parry | BofA Global Research |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Brandon Folkes | H.C. Wainwright & Co. |